Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (174 out of 246)

Industry: Medical - Products

Zacks News

Zacks Equity Research

HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View

HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.

Moumi Mondal headshot

Hologic's International Momentum Takes Shape: Will Execution Pay Off?

HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.

Zacks Equity Research

The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple

Wells Fargo, Abbott, and American Express lead Zacks highlights, while TSS surges on AI growth and MLP eyes land monetization.

Mark Vickery headshot

Top Stock Reports for Wells Fargo, Abbott & American Express

Wells Fargo gains post-Fed cap removal, Abbott rides strong devices pipeline, while AmEx sees growth but rising costs pinch margins.

Zacks Equity Research

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.

Zacks Equity Research

NVST or ABT: Which Is the Better Value Stock Right Now?

NVST vs. ABT: Which Stock Is the Better Value Option?

Moumi Mondal headshot

Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?

HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.

Zacks Equity Research

Stock Market News for Jul 18, 2025

U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.

Zacks Equity Research

Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?

Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Zacks Equity Research

Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround

Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Zacks Equity Research

Abbott (ABT) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Abbott (ABT) Q2 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Fight Off Powell Rumor, Close in the Green

A report that President Trump intended on firing Fed Chair Jerome Powell sent all major indexes into the loss column temporarily.

Mark Vickery headshot

Top Analyst Reports for Exxon Mobil, Home Depot & IBM

XOM, HD, and IBM face distinct macro pressures, but AI, Permian strength, and digital upgrades continue to fuel long-term growth.

Zacks Equity Research

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Shaun Pruitt headshot

3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS

The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.

Zacks Equity Research

Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?

BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.

Zacks Equity Research

Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Zacks Equity Research

ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus

Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.

Zacks Equity Research

Abbott (ABT) Suffers a Larger Drop Than the General Market: Key Insights

Abbott (ABT) reached $132.02 at the closing of the latest trading day, reflecting a -1.18% change compared to its last close.

Urmimala Biswas headshot

Smart Money Going in Senior Health: Key Stocks in Elderly Care

RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.

Zacks Equity Research

Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.